Currently out of the existing stock ratings of Joshua Jennings, 190 are a BUY (85.2%), 32 are a HOLD (14.35%), 1 are a SELL (0.45%).

Joshua Jennings

Work Performance Price Targets & Ratings Chart

Analyst Joshua Jennings, currently employed at TD COWEN, carries an average stock price target met ratio of 53.27% that have a potential upside of 25.01% achieved within 232 days.

Joshua Jennings’s has documented 444 price targets and ratings displayed on 34 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on HUMA, Humacyte at 11-Aug-2025.

Wall Street Analyst Joshua Jennings

Analyst best performing recommendations are on DCBO (DOCEBO).
The best stock recommendation documented was for TMDX (TRANSMEDICS GROUP) at 7/26/2022. The price target of $45 was fulfilled within 10 days with a profit of $8.94 (24.79%) receiving and performance score of 24.79.

Average potential price target upside

of $76.48 (38.22%) on PODD (INSULET).
of $41.37 (38.39%) on JNJ (JOHNSON & JOHNSON).
of $37.93 (17.81%) on SYK (STRYKER).

ABT Abbott Laboratories BAX Baxter International BSX Boston Scientific Corp ESTA Establishment Labs Holdings EW Edwards Lifesciences Corp GILD Gilead Sciences HUMA Humacyte JNJ Johnson & Johnson MDT Medtronic PLC NUVA NuVasive OM Outset Medical SYK Stryker TMDX TransMedics Group ZBH Zimmer Biomet Holdings ATEC Alphatec Holdings CERS Cerus APEN Apollo Endosurgery ITMR Itamar Medical Ltd PROF Profound Medical Corp AZYO Aziyo Biologics QTNT Quotient Ltd TNDM Tandem Diabetes Care DXCM DexCom STXS Stereotaxis MDWD Mediwound Ltd BDX Becton Dickinson and Company BFLY Butterfly Network CTSO Cytosorbents Crp PRCT Procept Biorobotics Corp RBOT Vicarious Surgical DCBO Docebo PODD Insulet VCEL Vericel Corp Ord CBLL CeriBell

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matt Miksic (BARCLAYS)